The research firm recently published its Pharma, Biotech & Medtech Half-Year Review that analyzes industry mergers and acquisitions, clinical trials and FDA drug approvals. As part of its report, it ranked the biggest drug approvals to date.
The five biggest drug approvals and their projected 2024 sales:
1. Skyrizi (AbbVie) treats psoriasis — $3.20 billion
2. Vyndaqel (Pfizer) treats heart disease caused by transthyretin mediated amyloidosis — $2.11 billion
3. Zolgensma (Novartis) treats spinal muscular atrophy — $1.57 billion
4. Mayzent (Novartis) treats relapsing multiple sclerosis — $1.31 billion
5. Balversa (Johnson & Johnson) treats advanced or metastatic bladder cancer — $1.15 billion
Access the full report here.
More articles on pharmacy:
CMS to cover CAR-T therapy nationwide
Colombia fines Pfizer $25K for drug price inflation
Jefferson Healthcare opens retail specialty pharmacy
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.